Mayinglong Pharmaceutical Group Co (SHSE:600993) Accounts Payable: ¥301 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600993 Mayinglong Pharmaceutical Group Co Ltd SHSE:600993
93 GF Score
Price ¥24.01
GF Value ¥29.63
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Mayinglong Pharmaceutical Group Co Accounts Payable?

Mayinglong Pharmaceutical Group Co SHSE:600993 +2.52% 93 Accounts Payable is ¥301 Mil as of Mar. 2026. GuruFocus rates SHSE:600993 with a GF Score™ of 93/100 and a GF Value™ of ¥29.63 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Mayinglong Pharmaceutical Group Co's Accounts Payable for the quarter that ended in Mar. 2026 was ¥301 Mil.

Mayinglong Pharmaceutical Group Co's quarterly Accounts Payable declined from Sep. 2025 (¥333 Mil) to Dec. 2025 (¥318 Mil) and declined from Dec. 2025 (¥318 Mil) to Mar. 2026 (¥301 Mil).

Mayinglong Pharmaceutical Group Co's annual Accounts Payable increased from Dec. 2023 (¥290 Mil) to Dec. 2024 (¥338 Mil) but then declined from Dec. 2024 (¥338 Mil) to Dec. 2025 (¥318 Mil).

Mayinglong Pharmaceutical Group Co Accounts Payable Related Terms

Mayinglong Pharmaceutical Group Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Mayinglong Pharmaceutical Group Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayinglong Pharmaceutical Group Co Accounts Payable Chart

Mayinglong Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 156.82 284.74 289.69 337.66 318.20

Mayinglong Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 350.15 378.95 333.42 318.20 301.23
SHSE:600993
93GF Score
Mayinglong Pharmaceutical Group Co Ltd SHSE:600993
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayinglong Pharmaceutical Group Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥301 Mil mean?
Mayinglong Pharmaceutical Group Co (SHSE:600993) has a Accounts Payable of ¥301 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Mayinglong Pharmaceutical Group Co and its competitors.
Is Mayinglong Pharmaceutical Group Co's Accounts Payable too high?
Mayinglong Pharmaceutical Group Co's current Accounts Payable is ¥301 Mil. Overall, Mayinglong Pharmaceutical Group Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mayinglong Pharmaceutical Group Co's Accounts Payable compare to ZTS?
Mayinglong Pharmaceutical Group Co's Accounts Payable of ¥301 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Mayinglong Pharmaceutical Group Co and its competitors. Mayinglong Pharmaceutical Group Co's current Accounts Payable is ¥301 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayinglong Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co (SHSE:600993) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.63, compared to a current price of ¥24.01 — trading 19% below its estimated fair value. The current Accounts Payable is ¥301 Mil. Mayinglong Pharmaceutical Group Co's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Mayinglong Pharmaceutical Group Co (SHSE:600993), the current Accounts Payable is ¥301 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayinglong Pharmaceutical Group Co (SHSE:600993) Overvalued in 2026?

Based on GuruFocus' analysis, Mayinglong Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥24.01 is trading 19% below its estimated GF Value™ of ¥29.63. GuruFocus considers Mayinglong Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600993:

  • Accounts Payable: ¥301 Mil
  • GF Value™: ¥29.63 vs. price of ¥24.01 (19% below fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600993 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayinglong Pharmaceutical Group Co Business Description

Address No. 100 Zhoujiawan, Nanhu, Wuchang District, Wuhan, Hubei, CHN, 430064
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
93GF Score

Get the complete analysis for SHSE:600993

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.01
Price
¥29.63
GF Value